Evrofarma SA

ATSE:EVROF Stok Raporu

Piyasa değeri: €19.1m

Evrofarma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Evrofarma has a total shareholder equity of €17.6M and total debt of €16.9M, which brings its debt-to-equity ratio to 96.1%. Its total assets and total liabilities are €49.6M and €31.9M respectively. Evrofarma's EBIT is €3.4M making its interest coverage ratio 2.6. It has cash and short-term investments of €470.0K.

Anahtar bilgiler

96.1%

Borç/özkaynak oranı

€16.95m

Borç

Faiz karşılama oranı2.6x
Nakit€470.00k
Eşitlik€17.63m
Toplam yükümlülükler€31.93m
Toplam varlıklar€49.56m

Son finansal sağlık güncellemeleri

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

Recent updates

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Oct 02
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29
Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06
Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Jan 05
Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Sep 15
Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Oct 04
We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

May 19
Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Feb 22
Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Dec 29
Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Nov 22
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EVROF's short term assets (€19.0M) exceed its short term liabilities (€13.8M).

Uzun Vadeli Yükümlülükler: EVROF's short term assets (€19.0M) exceed its long term liabilities (€18.1M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EVROF's net debt to equity ratio (93.5%) is considered high.

Borcun Azaltılması: EVROF's debt to equity ratio has reduced from 149% to 96.1% over the past 5 years.

Borç Kapsamı: EVROF's debt is well covered by operating cash flow (28%).

Faiz Kapsamı: EVROF's interest payments on its debt are not well covered by EBIT (2.6x coverage).

Bilanço

Sağlıklı şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y